Global group finalises management document
This article was originally published in Clinica
The Global Harmonisation Task Force (GHTF) now has a blueprint for its future management that satisfies industry and regulators alike. The new document is expected to be endorsed by the GHTF plenary, to be held in Ottawa, Canada, in September.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.